Thymalfasin

CAS No.: 69440-99-9

Linaclotide Chemical Structure

Molecular formula: C₁₂₉H₂₁₅N₃₃O₅₅

Molecular weight:3108.275

Patent period: —

Dositive specifications:–

Injection: —

Oral tablets: —

Injection:–

Biological Activity

Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.

Chemical Properties

ACTIONS	—
CAS NO.	69440-99-9
FORMULA	C₁₂₉H₂₁₅N₃₃O₅₅
M.WT	3108.3142
PURITY	99%
CAS Number	69440-99-9
STORAGE	Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Online Inquiry

NASH

The number of patients with non -alcoholic fatty liver patients around the world is on a rise, from 1.55 billion people in 2016 to 1.76 billion in 2020, with a compound annual growth rate of 3.1%;

Other Drug Peptide

Terzapitide NEW

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Semaglutide NEW

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.

Retatrutide NEW

Retatrutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR), glucose-dependent insulin- promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and related metabolic disorders.

Cagrilintide NEW

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acting as a nonselective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake.

Linaclotide NEW

Linaclotide is a potent and selective guanylate cyclase C agonist, developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.

BESTBELL